Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

March 24, 2014

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Clinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Malignant Solid NeoplasmMetastatic MelanomaUnresectable Melanoma
Interventions
PROCEDURE

Biopsy Procedure

Undergo biopsy

PROCEDURE

Biospecimen Collection

Undergo collection of blood samples

PROCEDURE

Computed Tomography

Undergo CT

DRUG

Dabrafenib

Given PO

PROCEDURE

Echocardiography Test

Undergo echocardiography

OTHER

Laboratory Biomarker Analysis

Correlative studies

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

PROCEDURE

Multigated Acquisition Scan

Undergo multigated acquisition scan

BIOLOGICAL

Navitoclax

Given PO

OTHER

Pharmacological Study

Correlative studies

DRUG

Trametinib

Given PO

Trial Locations (49)

10016

Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York

10032

NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York

19107

Thomas Jefferson University Hospital, Philadelphia

27599

UNC Lineberger Comprehensive Cancer Center, Chapel Hill

27710

Duke University Medical Center, Durham

33136

University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami

33146

UM Sylvester Comprehensive Cancer Center at Coral Gables, Coral Gables

33176

UM Sylvester Comprehensive Cancer Center at Kendall, Miami

33180

UM Sylvester Comprehensive Cancer Center at Aventura, Aventura

33324

UM Sylvester Comprehensive Cancer Center at Plantation, Plantation

33442

UM Sylvester Comprehensive Cancer Center at Deerfield Beach, Deerfield Beach

33612

Moffitt Cancer Center - McKinley Campus, Tampa

Moffitt Cancer Center, Tampa

43210

Ohio State University Comprehensive Cancer Center, Columbus

52242

University of Iowa/Holden Comprehensive Cancer Center, Iowa City

55905

Mayo Clinic in Rochester, Rochester

60611

Northwestern University, Chicago

63110

Washington University School of Medicine, St Louis

63129

Siteman Cancer Center-South County, St Louis

63136

Siteman Cancer Center at Christian Hospital, St Louis

63141

Siteman Cancer Center at West County Hospital, Creve Coeur

63376

Siteman Cancer Center at Saint Peters Hospital, City of Saint Peters

64064

University of Kansas Cancer Center - Lee's Summit, Lee's Summit

64108

University Health Truman Medical Center, Kansas City

64116

University of Kansas Cancer Center at North Kansas City Hospital, North Kansas City

64154

University of Kansas Cancer Center - North, Kansas City

66044

Lawrence Memorial Hospital, Lawrence

66061

The University of Kansas Cancer Center - Olathe, Olathe

66160

University of Kansas Cancer Center, Kansas City

66205

University of Kansas Clinical Research Center, Fairway

University of Kansas Hospital-Westwood Cancer Center, Westwood

66210

University of Kansas Cancer Center-Overland Park, Overland Park

66211

University of Kansas Hospital-Indian Creek Campus, Overland Park

66606

University of Kansas Health System Saint Francis Campus, Topeka

66762

Mercy Hospital Pittsburg, Pittsburg

67401

Salina Regional Health Center, Salina

67601

HaysMed, Hays

77030

M D Anderson Cancer Center, Houston

80045

UCHealth University of Colorado Hospital, Aurora

85054

Mayo Clinic Hospital in Arizona, Phoenix

85259

Mayo Clinic in Arizona, Scottsdale

90033

Los Angeles General Medical Center, Los Angeles

USC / Norris Comprehensive Cancer Center, Los Angeles

92663

USC Norris Oncology/Hematology-Newport Beach, Newport Beach

92868

UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange

95817

University of California Davis Comprehensive Cancer Center, Sacramento

02114

Massachusetts General Hospital Cancer Center, Boston

02215

Dana-Farber Cancer Institute, Boston

08903

Rutgers Cancer Institute of New Jersey, New Brunswick

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT01989585 - Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma | Biotech Hunter | Biotech Hunter